Rusty, even with the white knight coming to AURX rescue I find it disturbing that no large pharma/biotech pursued AURX
for its technology. It could be as in many cases that those large companies were unwilling to put the dinero out themselves while waiting for the smaller company to do the bulk of the leg work until late phase II or beginning of phase III.
There is one thing even CYGX topical cannot address concerning Herpes, and that is it's ability to
go "dormant" along nerve fibres in those hard to reach places.
The reason I like CYGX is the enormous potential not only for herpes, but for other dermatological conditions as well as sepsis and a whole host of other applications both animal and plant. Agriculture alone could really use a technology like ssDNA. Herpes topical is Cytos attempt at getting something to market. They don't expect IMO for it to be their flagship
product. In getting it to market they can prove that their technology is safe effective, and that they have the know how to get it approved. Big pharmas like that sort of thing. Sky is the limit after that.
This is still a high risk stock to invest in right now, but I like its chance right now. Large pharmas are aware of the work being done by CYGX. I know they are. I've talked to several people associated with large pharmas who know of Cytogenix. Almost every on of them said that CYGX was a very compelling story that one day may get to be told.
I think more than ever this company is in the right place at exactly the right time.
JMO though.
You obviously have some good contacts. Sorry I can came off somewhat flip yesterday.
Good luck to AuRx and good luck to us.
News 
Market Data 
Discover 
AI
